Pα+ Psychedelic Bulletin #154: Public & Industry Respond to DEA’s Renewed DOI and DOC Scheduling Plan; TARA Mind Scores $8m Seed; Updates on State Psychedelics Programs
- Public and Industry Respond to DEA’s Renewed Plan to Place DOI and DOC in Schedule I
- Updates on State Psychedelics Programs
- Fourth Time Lucky for California Psychedelic Policy Reform?
- Backlash in Oregon
- Updated Oregon Psilocybin Services Rules
- Colorado Natural Medicine Updates
- Mass. Legislature Considers Legal Psychedelics
- TARA Mind Scores $8M Seed Round
- Other News
- No New Psychiatric Drugs for Europeans in 2023
- Hallucinogen-Associated ER Visits
- Psychedelic Drug Development Clippings
- NIDA Grant for Psychedelics in SUDS Opens Sunday
- News Clippings
Companies, organisations and drug candidates mentioned in this Bulletin include: atai Life Sciences, TARA Mind, GH Research, Cybin, Psilera, Incannex...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In